Salud financiera de hoja de balance de Opthea

Salud financiera controles de criterios 1/6

Opthea tiene un patrimonio de los accionistas total de $-46.9M y una deuda total de $180.8M, lo que sitúa su ratio deuda-patrimonio en -385.3%. Sus activos y pasivos totales son $166.5M y $213.4M respectivamente.

Información clave

-385.3%

Ratio deuda-patrimonio

US$180.77m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$157.07m
Patrimonio	-US$46.91m
Total pasivo	US$213.41m
Activos totales	US$166.50m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

Jul 21

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Mar 24

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

Dec 09

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Oct 12

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Aug 24

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Mar 01

What Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?

Dec 13

Análisis de la situación financiera

Pasivos a corto plazo: OPT tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: OPT tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: OPT tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: OPT tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: OPT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: OPT tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 44.5% cada año

Salud financiera de hoja de balance de Opthea

Salud financiera controles de criterios 1/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Opthea Limited' ADR Deleted from Other OTC

Recent updates

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

New major risk - Financial position

Consensus revenue estimates increase by 13%

New minor risk - Profitability

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Price target decreased to AU$2.95

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Price target decreased to AU$4.24

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Independent Non-Executive Director exercised options to buy AU$1.1m worth of stock.

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: AU$1.75

New 90-day low: AU$1.81

Analysts update estimates